Table 3. Correlation between predictors and pulmonary embolism by univariate and multivariate logistic regression analysis.

	Univariate		Multivariate
Variable	OR (95%CI)	P value	OR (95%CI)	P value
Age(yr)	1.21(0.72–2.13)	0.08	-	-
Male			1(reference)
Female	1.52(0.88–2.26)	0.03	-	-
Smoking	history(N)		1(reference)
Smoking history(Y)	1.16(0.63–1.92)	0.17	-	-
SCLC			1(reference)
NSCLC	2.95(2.02–3.81)	0.01	2.88(1.97–3.78)	0.008
Adenocarcinoma	3.04(2.18–3.94)	0.003	2.93(2.19-4.14)	0.005
Squamous	1.82(0.81–3.25)	0.02	-	-
Stage I			1(reference)
Stage II	1.23(0.66–2.19)	0.23	-	-
Stage III	2.14(1.08–3.54)	0.02	-	-
Stage IV	2.95(1.99–4.18)	0.005	2.90(1.92–4.57)	0.002
Chemotherapy	3.28(2.11–4.58)	0.007	3.32(2.24–5.17)	0.004
Cancer surgery	4.17(2.63–4.88)	< 0.001	4.33(2.36–4.92)	< 0.001
Anticoagulation(LCR)	0.83(0.26–1.54)	0.03	-	-
Coagulation(LCR)	5.35(3.97–7.96)	< 0.001	5.19(3.33–8.64)	< 0.001
Progression	2.64(1.38–4.10)	0.003	2.72(1.46–4.33)	0.007
Recurrence	2.73(1.41–4.27)	0.006	2.75(1.22–4.39)	0.001
DVT	10.09(5.28–16.34)	< 0.001	10.62(4.94–18.08)	< 0.001
D-Dimer(mg/L)	6.09(3.21–7.17)	< 0.001	6.16(3.03–8.15)	< 0.001
CEA(ng/ml)	3.66(1.87–5.43)	0.008	3.71(1.78–5.38)	0.003
SCC(ng/ml)	1.97(0.38–3.65)	0.04	-	-
CYFRA21-1(ng/ml)	2.01(1.03–3.26)	0.002	-	-
NSE(ng/ml)	1.73(0.85–2.61)	0.01	-	-
ProGRP(pg/ml)	1.89(0.73–2.94)	0.03	-	-
TMs panel(abnormal TMs)	5.85(2.78–8.97)	< 0.001	5.98(2.36–9.04)	< 0.001

Note: OR: odds ratio; SCLC: small cell lung cancer; NSCLC: non small cell lung cancer; Stage: TNM stage; LCR: lung cancer related; DVT: deep venous thromboembolism; CEA: carcinoembryonic antigen; SCC: squamous cell carcinoma antigen; CYFRA21-1:cytokeratin 19 fragment; NSE: neuron-specific enolase; ProGRP: progastrin-releasing peptide; TMs: tumor markers